Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Lymphoid 1

Conditions

Prostatic Neoplasms 2Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 123Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67abiraterone 51atezolizumab 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39darolutamide 39Sorafenib 39apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Inosine Monophosphate × Genitourinary × Clear all
NCT07474051 2026-03-16

PERSIST

AvenCell Therapeutics, Inc.

Enrolling by invitation
178 enrolled
GenitourinaryLymphoidOther hematologic neoplasm

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT04633148 2024-04-23

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

AvenCell Therapeutics, Inc.

Phase 1 Terminated
16 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡